Free Trial
OTCMKTS:ELTP

Elite Pharmaceuticals (ELTP) Stock Price, News & Analysis

Elite Pharmaceuticals logo
$0.51
+0.01 (+2.00%)
(As of 11/4/2024 ET)

About Elite Pharmaceuticals Stock (OTCMKTS:ELTP)

Key Stats

Today's Range
$0.50
$0.53
50-Day Range
$0.25
$0.71
52-Week Range
$0.10
$0.75
Volume
1.45 million shs
Average Volume
5.15 million shs
Market Capitalization
$544.92 million
P/E Ratio
51.06
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals. It owns, licenses, manufactures, and sells various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand, as well as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, attention deficit, and infection. Further, the company is developing a range of abuse deterrent opioid products. Elite Pharmaceuticals, Inc. was incorporated in 1997 and is headquartered in Northvale, New Jersey.

Elite Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
19th Percentile Overall Score

ELTP MarketRank™: 

Elite Pharmaceuticals scored higher than 19% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Elite Pharmaceuticals is 51.06, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 134.67.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Elite Pharmaceuticals is 51.06, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 135.88.

  • Price to Book Value per Share Ratio

    Elite Pharmaceuticals has a P/B Ratio of 10.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.19% of the outstanding shares of Elite Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Elite Pharmaceuticals has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Elite Pharmaceuticals has recently decreased by 1.57%, indicating that investor sentiment is improving.
  • Dividend Yield

    Elite Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Elite Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.19% of the outstanding shares of Elite Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Elite Pharmaceuticals has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Elite Pharmaceuticals has recently decreased by 1.57%, indicating that investor sentiment is improving.
  • Search Interest

    6 people have searched for ELTP on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • MarketBeat Follows

    6 people have added Elite Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Elite Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    14.42% of the stock of Elite Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 0.01% of the stock of Elite Pharmaceuticals is held by institutions.

  • Read more about Elite Pharmaceuticals' insider trading history.
Receive ELTP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Elite Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ELTP Stock News Headlines

War on Elon Escalates…
A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.
ELITE PHARMACEUTICALS INC
Intercontinental Exchange Inc (IC2.BE)
7 Strong Buy Penny Stocks to Buy Now: June 2024
See More Headlines

ELTP Stock Analysis - Frequently Asked Questions

Elite Pharmaceuticals' stock was trading at $0.14 at the start of the year. Since then, ELTP shares have increased by 264.4% and is now trading at $0.5101.
View the best growth stocks for 2024 here
.

Elite Pharmaceuticals, Inc. (OTCMKTS:ELTP) announced its quarterly earnings data on Thursday, June, 14th. The specialty pharmaceutical company reported $0.00 EPS for the quarter. The specialty pharmaceutical company earned $1.60 million during the quarter. Elite Pharmaceuticals had a net margin of 29.47% and a trailing twelve-month return on equity of 40.72%.

Shares of ELTP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Elite Pharmaceuticals investors own include Research Frontiers (REFR), Co-Diagnostics (CODX), Novavax (NVAX), FuelCell Energy (FCEL), Onconova Therapeutics (ONTX), iBio (IBIO) and Inovio Pharmaceuticals (INO).

Company Calendar

Last Earnings
6/14/2018
Today
11/04/2024
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:ELTP
Employees
40
Year Founded
N/A

Profitability

Net Income
$20.11 million
Pretax Margin
0.02%

Debt

Sales & Book Value

Annual Sales
$56.62 million
Cash Flow
$0.03 per share
Book Value
$0.05 per share

Miscellaneous

Outstanding Shares
1,068,270,000
Free Float
914,228,000
Market Cap
$544.92 million
Optionable
Not Optionable
Beta
0.17
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (OTCMKTS:ELTP) was last updated on 11/5/2024 by MarketBeat.com Staff
From Our Partners